Compare · EDSA vs KRYS
EDSA vs KRYS
Side-by-side comparison of Edesa Biotech Inc. (EDSA) and Krystal Biotech Inc. (KRYS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. EDSA focuses on Biotechnology: Pharmaceutical Preparations, while KRYS focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- KRYS is the larger of the two at $9.13B, about 207.9x EDSA ($43.9M).
- Over the past year, EDSA is up 157.7% and KRYS is up 129.8% - EDSA leads by 27.8 points.
- EDSA has been more active in the news (15 items in the past 4 weeks vs 7 for KRYS).
- KRYS has more recent analyst coverage (17 ratings vs 1 for EDSA).
- Company
- Edesa Biotech Inc.
- Krystal Biotech Inc.
- Price
- $4.71-11.12%
- $317.00+2.39%
- Market cap
- $43.9M
- $9.13B
- 1M return
- -71.51%
- +1.61%
- 1Y return
- +157.65%
- +129.83%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 15
- 7
- Recent ratings
- 1
- 17
Edesa Biotech Inc.
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Krystal Biotech Inc.
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and acne scars; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx for other rare lung disease. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Latest EDSA
- Edesa Biotech Inc. filed SEC Form 8-K: Other Events
- Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury
- Chief Executive Officer Nijhawan Pardeep was granted 1,671 shares, increasing direct ownership by 0.23% to 731,134 units (SEC Form 4)
- Director Marshall Patrick was granted 19,000 shares, increasing direct ownership by 36% to 71,666 units (SEC Form 4)
- Director Macdonald Sean Arthur was granted 19,000 shares, increasing direct ownership by 86% to 41,054 units (SEC Form 4)
- Director Chypyha Joan was granted 19,000 shares, increasing direct ownership by 172% to 30,029 units (SEC Form 4)
- Chief Financial Officer Weiler Peter J. was granted 64,609 shares, increasing direct ownership by 99% to 129,609 units (SEC Form 4)
- President Brooks Michael J was granted 64,609 shares, increasing direct ownership by 28% to 291,479 units (SEC Form 4)
- Director Sistilli Carlo was granted 19,000 shares, increasing direct ownership by 62% to 49,417 units (SEC Form 4)
- Director Olson Charles V was granted 19,000 shares, increasing direct ownership by 173% to 30,000 units (SEC Form 4)
Latest KRYS
- President, R&D Krishnan Suma sold $7,702,825 worth of shares (25,000 units at $308.11) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,378,155 units (SEC Form 4)
- President and CEO Krishnan Krish S sold $7,702,984 worth of shares (25,000 units at $308.12) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,450,253 units (SEC Form 4)
- SEC Form 144 filed by Krystal Biotech Inc.
- SEC Form 144 filed by Krystal Biotech Inc.
- EVP, General Counsel Thomas John Charles sold $193,903 worth of shares (642 units at $302.03) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
- Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
- Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
- Krystal Biotech to Present at BofA Securities 2026 Health Care Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by Krystal Biotech Inc.
- Krystal Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits